Pharmaceutical sales company prepares for controlled sales
Release time:
2020-08-14
Attends Academic Conference to Discuss Successful Experience
Pharmaceutical Sales Company to Prepare for Sales Control
News 9# December 7 - 9 , The 15th National Psychiatric Conference of the Chinese Medical Association and the 7th Cross-Strait Psychiatric Conference on Children and Adolescents were grandly held in Hangzhou. The person in charge of the pharmaceutical sales company and terminal marketing personnel participated in the event. Experts and doctors in the field study and exchange.
This conference comprehensively demonstrated the new achievements in the clinical prevention and basic research of mental disorders in my country, and introduced new international developments, new discoveries and new hot spots. There were 50 special sessions and 13 special sessions for free exchange of submitted papers. The number of registered experts and doctors was as high as 3300 . 60 participating enterprises signed 22 satellite sessions and set up 72 booths. Zhou Wenyi, general manager of the pharmaceutical sales company, and Xu Junxiong, executive vice president, have extensive contact with booth enterprises, listened to the front-line sales experience of relevant enterprises, collected product publicity materials and gifts, and prepared for the future development of the sales control model. During the
meeting, General Manager Zhou Wenyi and his sales control personnel visited Zhang Wenjie, chairman of Nuclear Power Xinjian Industry. The annual sales volume of Yijunkang (compound Lactobacillus acidophilus tablets) of the enterprise is as high as .8 billion RMB. The original sales channel is hospitals. Last year, he started to enter the terminal chain market and has signed contracts to cooperate with nearly ,400 large chains. The two sides exchanged views on developing the terminal chain market. Zhang Wenjie talked about the development experience. He said that only by choosing a chain with strong execution can the next effect be better uploaded. It is necessary to create a model market and pay attention to the sharp knife of "academic training". Fully control the price of products and leave sufficient room for the promotion of later marketing activities.
9 April 8 , relevant personnel also visited clove garden headquarters and clove clinic. clove garden is now the largest professional interactive platform for doctors in China. the number of registered doctors is 200 , the number of real-name certified doctors is 137 , and the number of wechat fans is 600 . in the face of doctors using data, platform, interaction and other methods to accurately educate medicine, in the face of patients through health knowledge to promote chronic disease care services. While learning and understanding the operation mode of clove garden, we seek project cooperation points and do preliminary research work for the academic promotion of later products of pharmaceutical companies. (Xu Yuting)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page